INGREZZA Normalized: ingrezza |
Drug |
Neurocrine BioSciences, Inc. |
$61,784.78 |
80 |
2025 |
Source payment records
-
2025-01-08 · Neurocrine BioSciences, Inc. · $8.05 ·
Open Payments source
-
2025-02-04 · Neurocrine BioSciences, Inc. · $1,500.00 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $3,563.00 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $915.64 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $835.97 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $318.07 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $101.44 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $90.00 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $78.40 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $28.59 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $26.71 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $14.03 ·
Open Payments source
-
2025-02-05 · Neurocrine BioSciences, Inc. · $10.47 ·
Open Payments source
-
2025-02-28 · Neurocrine BioSciences, Inc. · $159.14 ·
Open Payments source
-
2025-02-28 · Neurocrine BioSciences, Inc. · $89.60 ·
Open Payments source
-
2025-02-28 · Neurocrine BioSciences, Inc. · $28.80 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $485.94 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $49.57 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $43.51 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $36.48 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $24.96 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $18.09 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $9.18 ·
Open Payments source
-
2025-03-01 · Neurocrine BioSciences, Inc. · $6.37 ·
Open Payments source
-
2025-03-02 · Neurocrine BioSciences, Inc. · $1,184.97 ·
Open Payments source
-
2025-03-02 · Neurocrine BioSciences, Inc. · $38.73 ·
Open Payments source
-
2025-03-11 · Neurocrine BioSciences, Inc. · $1,500.00 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $3,563.00 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $926.97 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $287.35 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $125.00 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $78.40 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $72.90 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $34.68 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $23.68 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $9.15 ·
Open Payments source
-
2025-03-13 · Neurocrine BioSciences, Inc. · $3.49 ·
Open Payments source
-
2025-03-25 · Neurocrine BioSciences, Inc. · $7,875.00 ·
Open Payments source
-
2025-03-25 · Neurocrine BioSciences, Inc. · $1,500.00 ·
Open Payments source
-
2025-04-23 · Neurocrine BioSciences, Inc. · $3,563.00 ·
Open Payments source
-
2025-04-23 · Neurocrine BioSciences, Inc. · $2,438.00 ·
Open Payments source
-
2025-04-23 · Neurocrine BioSciences, Inc. · $524.96 ·
Open Payments source
-
2025-04-23 · Neurocrine BioSciences, Inc. · $346.27 ·
Open Payments source
-
2025-04-23 · Neurocrine BioSciences, Inc. · $138.51 ·
Open Payments source
-
2025-04-30 · Neurocrine BioSciences, Inc. · $3,563.00 ·
Open Payments source
-
2025-04-30 · Neurocrine BioSciences, Inc. · $2,438.00 ·
Open Payments source
-
2025-04-30 · Neurocrine BioSciences, Inc. · $810.96 ·
Open Payments source
-
2025-04-30 · Neurocrine BioSciences, Inc. · $750.45 ·
Open Payments source
-
2025-04-30 · Neurocrine BioSciences, Inc. · $122.10 ·
Open Payments source
-
2025-05-08 · Neurocrine BioSciences, Inc. · $6.60 ·
Open Payments source
-
2025-05-30 · Neurocrine BioSciences, Inc. · $20.07 ·
Open Payments source
-
2025-06-12 · Neurocrine BioSciences, Inc. · $1,500.00 ·
Open Payments source
-
2025-06-19 · Neurocrine BioSciences, Inc. · $81.03 ·
Open Payments source
-
2025-06-20 · Neurocrine BioSciences, Inc. · $117.13 ·
Open Payments source
-
2025-06-21 · Neurocrine BioSciences, Inc. · $670.19 ·
Open Payments source
-
2025-06-21 · Neurocrine BioSciences, Inc. · $26.08 ·
Open Payments source
-
2025-07-07 · Neurocrine BioSciences, Inc. · $1,490.97 ·
Open Payments source
-
2025-07-11 · Neurocrine BioSciences, Inc. · $4,687.50 ·
Open Payments source
-
2025-07-11 · Neurocrine BioSciences, Inc. · $187.62 ·
Open Payments source
-
2025-07-19 · Neurocrine BioSciences, Inc. · $664.26 ·
Open Payments source
-
2025-07-19 · Neurocrine BioSciences, Inc. · $147.70 ·
Open Payments source
-
2025-07-19 · Neurocrine BioSciences, Inc. · $147.28 ·
Open Payments source
-
2025-07-19 · Neurocrine BioSciences, Inc. · $145.62 ·
Open Payments source
-
2025-07-19 · Neurocrine BioSciences, Inc. · $80.00 ·
Open Payments source
-
2025-08-15 · Neurocrine BioSciences, Inc. · $5,625.00 ·
Open Payments source
-
2025-08-22 · Neurocrine BioSciences, Inc. · $236.23 ·
Open Payments source
-
2025-08-22 · Neurocrine BioSciences, Inc. · $125.46 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $265.07 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $233.48 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $121.93 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $68.48 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $48.39 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $45.65 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $24.19 ·
Open Payments source
-
2025-11-05 · Neurocrine BioSciences, Inc. · $24.19 ·
Open Payments source
-
2025-11-28 · Neurocrine BioSciences, Inc. · $4,500.00 ·
Open Payments source
-
2025-11-28 · Neurocrine BioSciences, Inc. · $66.52 ·
Open Payments source
-
2025-11-28 · Neurocrine BioSciences, Inc. · $39.20 ·
Open Payments source
-
2025-11-28 · Neurocrine BioSciences, Inc. · $17.06 ·
Open Payments source
-
2025-11-28 · Neurocrine BioSciences, Inc. · $11.30 ·
Open Payments source
|
INVEGA SUSTENNA Normalized: invega sustenna |
Drug |
Janssen Pharmaceuticals, Inc |
$51,220.77 |
51 |
2025 |
Source payment records
-
2025-01-07 · Janssen Pharmaceuticals, Inc · $24.74 ·
Open Payments source
-
2025-01-07 · Janssen Pharmaceuticals, Inc · $16.31 ·
Open Payments source
-
2025-01-07 · Janssen Pharmaceuticals, Inc · $132.07 ·
Open Payments source
-
2025-03-10 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-03-20 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-03-28 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-04-03 · Janssen Pharmaceuticals, Inc · $107.95 ·
Open Payments source
-
2025-04-04 · Janssen Pharmaceuticals, Inc · $1,291.95 ·
Open Payments source
-
2025-04-07 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-04-14 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-04-18 · Janssen Pharmaceuticals, Inc · $6,660.00 ·
Open Payments source
-
2025-04-22 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-04-22 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-05-01 · Janssen Pharmaceuticals, Inc · $86.67 ·
Open Payments source
-
2025-05-05 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-05-06 · Janssen Pharmaceuticals, Inc · $744.58 ·
Open Payments source
-
2025-05-20 · Janssen Pharmaceuticals, Inc · $1,035.32 ·
Open Payments source
-
2025-05-22 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-05-23 · Janssen Pharmaceuticals, Inc · $49.50 ·
Open Payments source
-
2025-05-24 · Janssen Pharmaceuticals, Inc · $74.50 ·
Open Payments source
-
2025-06-06 · Janssen Pharmaceuticals, Inc · $566.65 ·
Open Payments source
-
2025-06-10 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-06-10 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-07-09 · Janssen Pharmaceuticals, Inc · $555.00 ·
Open Payments source
-
2025-07-11 · Janssen Pharmaceuticals, Inc · $829.27 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $30.23 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $35.16 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $30.63 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $371.58 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $2,220.00 ·
Open Payments source
-
2025-08-06 · Janssen Pharmaceuticals, Inc · $111.94 ·
Open Payments source
-
2025-08-07 · Janssen Pharmaceuticals, Inc · $696.52 ·
Open Payments source
-
2025-08-08 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-09-02 · Janssen Pharmaceuticals, Inc · $829.27 ·
Open Payments source
-
2025-09-10 · Janssen Pharmaceuticals, Inc · $114.35 ·
Open Payments source
-
2025-09-10 · Janssen Pharmaceuticals, Inc · $172.41 ·
Open Payments source
-
2025-09-11 · Janssen Pharmaceuticals, Inc · $514.21 ·
Open Payments source
-
2025-09-11 · Janssen Pharmaceuticals, Inc · $137.70 ·
Open Payments source
-
2025-09-15 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-09-26 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-10-16 · Janssen Pharmaceuticals, Inc · $111.13 ·
Open Payments source
-
2025-10-17 · Janssen Pharmaceuticals, Inc · $1,174.50 ·
Open Payments source
-
2025-10-20 · Janssen Pharmaceuticals, Inc · $3,330.00 ·
Open Payments source
-
2025-10-24 · Janssen Pharmaceuticals, Inc · $29.08 ·
Open Payments source
-
2025-10-24 · Janssen Pharmaceuticals, Inc · $25.00 ·
Open Payments source
-
2025-10-24 · Janssen Pharmaceuticals, Inc · $123.78 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $157.25 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $22.84 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $20.49 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $183.69 ·
Open Payments source
-
2025-12-17 · Janssen Pharmaceuticals, Inc · $832.50 ·
Open Payments source
|
INVEGA TRINZA Normalized: invega trinza |
Drug |
Janssen Pharmaceuticals, Inc |
$50,688.73 |
46 |
2025 |
Source payment records
-
2025-01-07 · Janssen Pharmaceuticals, Inc · $24.74 ·
Open Payments source
-
2025-01-07 · Janssen Pharmaceuticals, Inc · $16.31 ·
Open Payments source
-
2025-01-07 · Janssen Pharmaceuticals, Inc · $132.07 ·
Open Payments source
-
2025-03-10 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-03-20 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-03-28 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-04-04 · Janssen Pharmaceuticals, Inc · $1,291.95 ·
Open Payments source
-
2025-04-07 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-04-14 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-04-18 · Janssen Pharmaceuticals, Inc · $6,660.00 ·
Open Payments source
-
2025-04-22 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-04-22 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-05-05 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-05-06 · Janssen Pharmaceuticals, Inc · $744.58 ·
Open Payments source
-
2025-05-20 · Janssen Pharmaceuticals, Inc · $1,035.32 ·
Open Payments source
-
2025-05-22 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-05-23 · Janssen Pharmaceuticals, Inc · $49.50 ·
Open Payments source
-
2025-05-24 · Janssen Pharmaceuticals, Inc · $74.50 ·
Open Payments source
-
2025-06-06 · Janssen Pharmaceuticals, Inc · $566.65 ·
Open Payments source
-
2025-06-10 · Janssen Pharmaceuticals, Inc · $1,110.00 ·
Open Payments source
-
2025-06-10 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-07-09 · Janssen Pharmaceuticals, Inc · $555.00 ·
Open Payments source
-
2025-07-11 · Janssen Pharmaceuticals, Inc · $829.27 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $30.23 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $35.16 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $30.63 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $371.58 ·
Open Payments source
-
2025-08-01 · Janssen Pharmaceuticals, Inc · $2,220.00 ·
Open Payments source
-
2025-08-07 · Janssen Pharmaceuticals, Inc · $696.52 ·
Open Payments source
-
2025-08-08 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-09-02 · Janssen Pharmaceuticals, Inc · $829.27 ·
Open Payments source
-
2025-09-10 · Janssen Pharmaceuticals, Inc · $172.41 ·
Open Payments source
-
2025-09-11 · Janssen Pharmaceuticals, Inc · $514.21 ·
Open Payments source
-
2025-09-11 · Janssen Pharmaceuticals, Inc · $137.70 ·
Open Payments source
-
2025-09-15 · Janssen Pharmaceuticals, Inc · $3,885.00 ·
Open Payments source
-
2025-09-26 · Janssen Pharmaceuticals, Inc · $5.50 ·
Open Payments source
-
2025-10-17 · Janssen Pharmaceuticals, Inc · $1,174.50 ·
Open Payments source
-
2025-10-20 · Janssen Pharmaceuticals, Inc · $3,330.00 ·
Open Payments source
-
2025-10-24 · Janssen Pharmaceuticals, Inc · $29.08 ·
Open Payments source
-
2025-10-24 · Janssen Pharmaceuticals, Inc · $25.00 ·
Open Payments source
-
2025-10-24 · Janssen Pharmaceuticals, Inc · $123.78 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $157.25 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $22.84 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $20.49 ·
Open Payments source
-
2025-11-06 · Janssen Pharmaceuticals, Inc · $183.69 ·
Open Payments source
-
2025-12-17 · Janssen Pharmaceuticals, Inc · $832.50 ·
Open Payments source
|
UZEDY Normalized: uzedy |
Drug |
Teva Pharmaceuticals USA, Inc. |
$28,626.01 |
37 |
2025 |
Source payment records
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $10.01 ·
Open Payments source
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $10.47 ·
Open Payments source
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $51.10 ·
Open Payments source
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $79.10 ·
Open Payments source
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $1,666.00 ·
Open Payments source
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $3,124.00 ·
Open Payments source
-
2025-01-22 · Teva Pharmaceuticals USA, Inc. · $8.01 ·
Open Payments source
-
2025-03-30 · Teva Pharmaceuticals USA, Inc. · $2,573.00 ·
Open Payments source
-
2025-06-18 · Teva Pharmaceuticals USA, Inc. · $142.80 ·
Open Payments source
-
2025-06-18 · Teva Pharmaceuticals USA, Inc. · $2,709.00 ·
Open Payments source
-
2025-10-19 · Teva Pharmaceuticals USA, Inc. · $368.00 ·
Open Payments source
-
2025-11-07 · Teva Pharmaceuticals USA, Inc. · $43.90 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $22.76 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $39.20 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $114.82 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $3,542.00 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $94.76 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $21.15 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $62.00 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $198.96 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $547.37 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $1,490.05 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $1,668.00 ·
Open Payments source
-
2025-12-02 · Teva Pharmaceuticals USA, Inc. · $39.20 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $38.50 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $46.40 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $392.48 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $675.68 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $1,556.06 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $1,668.00 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $86.53 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $121.83 ·
Open Payments source
-
2025-12-09 · Teva Pharmaceuticals USA, Inc. · $1,668.00 ·
Open Payments source
-
2025-12-10 · Teva Pharmaceuticals USA, Inc. · $44.93 ·
Open Payments source
-
2025-12-10 · Teva Pharmaceuticals USA, Inc. · $120.00 ·
Open Payments source
-
2025-12-10 · Teva Pharmaceuticals USA, Inc. · $3,542.00 ·
Open Payments source
-
2025-12-10 · Teva Pharmaceuticals USA, Inc. · $39.94 ·
Open Payments source
|
COBENFY Normalized: cobenfy |
Drug |
E.R. Squibb & Sons, L.L.C. |
$23,590.22 |
35 |
2025 |
Source payment records
-
2025-03-14 · E.R. Squibb & Sons, L.L.C. · $1,610.00 ·
Open Payments source
-
2025-04-16 · E.R. Squibb & Sons, L.L.C. · $161.59 ·
Open Payments source
-
2025-04-16 · E.R. Squibb & Sons, L.L.C. · $651.55 ·
Open Payments source
-
2025-04-16 · E.R. Squibb & Sons, L.L.C. · $125.00 ·
Open Payments source
-
2025-04-16 · E.R. Squibb & Sons, L.L.C. · $450.75 ·
Open Payments source
-
2025-05-05 · E.R. Squibb & Sons, L.L.C. · $4,140.00 ·
Open Payments source
-
2025-05-15 · E.R. Squibb & Sons, L.L.C. · $2,561.81 ·
Open Payments source
-
2025-05-15 · E.R. Squibb & Sons, L.L.C. · $20.35 ·
Open Payments source
-
2025-05-15 · E.R. Squibb & Sons, L.L.C. · $234.98 ·
Open Payments source
-
2025-05-22 · E.R. Squibb & Sons, L.L.C. · $227.46 ·
Open Payments source
-
2025-05-22 · E.R. Squibb & Sons, L.L.C. · $134.36 ·
Open Payments source
-
2025-05-22 · E.R. Squibb & Sons, L.L.C. · $565.80 ·
Open Payments source
-
2025-05-22 · E.R. Squibb & Sons, L.L.C. · $776.81 ·
Open Payments source
-
2025-05-29 · E.R. Squibb & Sons, L.L.C. · $39.58 ·
Open Payments source
-
2025-06-04 · E.R. Squibb & Sons, L.L.C. · $2,760.00 ·
Open Payments source
-
2025-06-13 · E.R. Squibb & Sons, L.L.C. · $4,140.00 ·
Open Payments source
-
2025-06-24 · E.R. Squibb & Sons, L.L.C. · $1,380.00 ·
Open Payments source
-
2025-06-24 · E.R. Squibb & Sons, L.L.C. · $1,380.00 ·
Open Payments source
-
2025-07-07 · E.R. Squibb & Sons, L.L.C. · $35.06 ·
Open Payments source
-
2025-07-11 · E.R. Squibb & Sons, L.L.C. · $77.00 ·
Open Payments source
-
2025-07-11 · E.R. Squibb & Sons, L.L.C. · $32.00 ·
Open Payments source
-
2025-07-11 · E.R. Squibb & Sons, L.L.C. · $30.74 ·
Open Payments source
-
2025-07-11 · E.R. Squibb & Sons, L.L.C. · $19.57 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $1,083.49 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 ·
Open Payments source
-
2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 ·
Open Payments source
-
2025-11-05 · E.R. Squibb & Sons, L.L.C. · $35.85 ·
Open Payments source
-
2025-11-05 · E.R. Squibb & Sons, L.L.C. · $170.10 ·
Open Payments source
-
2025-11-07 · E.R. Squibb & Sons, L.L.C. · $41.97 ·
Open Payments source
-
2025-11-07 · E.R. Squibb & Sons, L.L.C. · $16.63 ·
Open Payments source
|
Auvelity Normalized: auvelity |
Drug |
Axsome Therapeutics, Inc. |
$14,940.91 |
25 |
2025 |
Source payment records
-
2025-01-30 · Axsome Therapeutics, Inc. · $400.00 ·
Open Payments source
-
2025-03-06 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $29.45 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $125.13 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $60.36 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $48.79 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $32.93 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $45.30 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $78.04 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $26.77 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $677.97 ·
Open Payments source
-
2025-03-15 · Axsome Therapeutics, Inc. · $234.83 ·
Open Payments source
-
2025-03-18 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
-
2025-04-04 · Axsome Therapeutics, Inc. · $6,800.00 ·
Open Payments source
-
2025-05-16 · Axsome Therapeutics, Inc. · $48.73 ·
Open Payments source
-
2025-05-16 · Axsome Therapeutics, Inc. · $39.20 ·
Open Payments source
-
2025-05-16 · Axsome Therapeutics, Inc. · $234.41 ·
Open Payments source
-
2025-07-29 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
-
2025-09-15 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
-
2025-09-18 · Axsome Therapeutics, Inc. · $25.74 ·
Open Payments source
-
2025-11-07 · Axsome Therapeutics, Inc. · $33.26 ·
Open Payments source
-
2025-12-08 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
-
2025-12-09 · Axsome Therapeutics, Inc. · $400.00 ·
Open Payments source
-
2025-12-16 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
-
2025-12-23 · Axsome Therapeutics, Inc. · $800.00 ·
Open Payments source
|
ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug |
Luye Pharma (USA) Ltd. |
$11,523.01 |
9 |
2025 |
Source payment records
|
CAPLYTA Normalized: caplyta |
Drug |
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) |
$9,643.16 |
20 |
2025 |
Source payment records
-
2025-06-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,395.00 ·
Open Payments source
-
2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 ·
Open Payments source
-
2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 ·
Open Payments source
-
2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $35.00 ·
Open Payments source
-
2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 ·
Open Payments source
-
2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 ·
Open Payments source
-
2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 ·
Open Payments source
-
2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $325.97 ·
Open Payments source
-
2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $108.70 ·
Open Payments source
-
2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.39 ·
Open Payments source
-
2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.70 ·
Open Payments source
-
2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.70 ·
Open Payments source
-
2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.70 ·
Open Payments source
-
2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.51 ·
Open Payments source
-
2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.80 ·
Open Payments source
-
2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $53.90 ·
Open Payments source
-
2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.20 ·
Open Payments source
-
2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 ·
Open Payments source
-
2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 ·
Open Payments source
-
2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 ·
Open Payments source
|
VRAYLAR Normalized: vraylar |
Drug |
ABBVIE INC. |
$8,936.62 |
16 |
2025 |
Source payment records
|
LYBALVI Normalized: lybalvi |
Drug |
Alkermes, Inc. |
$4,950.41 |
7 |
2025 |
Source payment records
|
REXULTI Normalized: rexulti |
Drug |
Otsuka America Pharmaceutical, Inc. |
$3,536.26 |
5 |
2025 |
Source payment records
|
REJOYN Normalized: rejoyn |
Device |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
$3,113.30 |
6 |
2025 |
Source payment records
-
2025-01-03 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $2,516.00 ·
Open Payments source
-
2025-01-16 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $132.01 ·
Open Payments source
-
2025-01-16 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $22.66 ·
Open Payments source
-
2025-01-16 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $80.38 ·
Open Payments source
-
2025-07-11 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $161.00 ·
Open Payments source
-
2025-08-22 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $201.25 ·
Open Payments source
|
ARISTADA Normalized: aristada |
Drug |
Alkermes, Inc. |
$776.96 |
3 |
2025 |
Source payment records
|
AUSTEDO XR Normalized: austedo xr |
Drug |
Teva Pharmaceuticals USA, Inc. |
$420.13 |
2 |
2025 |
Source payment records
|
Qelbree Normalized: qelbree |
Drug |
Supernus Pharmaceuticals, Inc. |
$49.49 |
1 |
2025 |
Source payment records
|